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Recent inferences in imaging technology describe the presence of metabolically active 
brown adipose tissue (BAT) in human adults. Adrenergic activation through the signature 
protein of uncoupling protein-1 (UCP1) leads to significant energy expenditure. During 
the process of thermogenesis mediated by UCP1, functional BAT consumes intracellular 
lipid stores, thus, providing an avenue for therapeutic solution to combat metabolic 
disorders such as obesity. To date, there have been numerous studies done in humans to 
mine for possible gene targets to elucidate signaling mechanisms that regulate BAT 
differentiation and thermogenesis. Pharmacological intervention with specific interest in 
non-adrenergic activation of BAT is currently a much sought after goal. Amongst the 
many membrane bound proteins, solute carriers (SLCs) represent a class of genes that can 
serve as drug targets, capable of being modulated through non-adrenergic means for BAT 
enhancement. Despite high relevance to physiological insights in health and disease, 
SLCs remain to be a topic that is poorly studied. Hence, I undertook a genome-wide 
microarray study of brown and white differentiated adipocytes, and further verified SLC 
gene expressions using qPCR, Western blot and respirometry analysis. This systematic 
SLC study comprised functional brown adipocytes differentiated from stem cells derived 
from bone marrow mesenchymal stem cells (bm MSCs), adipose derived stem cells 
(hMADs) and subcutaneous stromal vascular fraction (SC-SVF) that demonstrated 
significant expression of UCP1 and evidence of uncoupled respiration ability. A total of 
five SLCs were verified to be robustly expressed in brown differentiated adipocytes from 
four different cell sources, of which two SLCs, SLC19A3 and SLC22A5, were reported 
to play key roles in energy metabolism. The results showed both SLCs possibly involved 
in the maintenance of BAT phenotype. The derived SLC marker panel provide an 
essential starting point for further molecular characterization of these identified SLCs. 
Here I report the first of its kind SLC study done in brown adipocytes differentiated from 
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Chapter 1: Introduction 
1.1.The global double burden of obesity and diabetes 
Famine and malnutrition throughout most of human history have prompted the need for 
efficient excess energy storage as a survival strategy. Essentially, storage of bodily fat, in 
the form of triglycerides that were gradually released over a long period of time, became 
the adaptive physiological process [1, 2]. With the advent of technology thereafter, access 
to high quality, amount and variety of food became readily available and led to improved 
health as well as increased body size [1]. Once thought to sustain survival, accumulation 
of fat due to high calorific intake, coupled with reduced physical activity, result in the 
enlargement of adipose tissue by increasing cell number (hyperplasia) and cell size 
(hypertrophy) to manage the excess energy intake [3], culminating in the progression of 
obesity [4]. According to the World Health Organization (WHO), obesity in adults is 
defined as having a Body-Mass Index (BMI) of greater than or equal to 30 kg/m2 [5, 6]. 
BMI is calculated from a person's weight in kilograms divided by the square of his height 
in meters. Global estimates show 600 million adults classified as obese, encompassing 
13% of the world’s adult population in 2014, with a worldwide prevalence that have 
more than doubled between 1980 and 2014. Simultaneously, 41 million of children under 
the age of 5 were obese or overweight in 2014 and nearly half of them lived in Asia [6]. 
Obesity remains to be one of the most neglected public health problems that afflicts both 
developing and developed countries, eclipsing malnutrition, infectious diseases and 
undernourishment [7].  The impaired energy homeostasis mechanism caused by obesity 
[4] engenders a non-exhaustive list of diseases including coronary heart disease, type II 
diabetes, high blood pressure, stroke, dyslipidemia, osteoarthritis and cancers [5, 8, 9]. 
Current practices for the treatment and management of obesity involve therapy 
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interventions that require lifestyle and dietary modifications, increased physical activities 
and use of medications to suppress food intake [4, 9]. Although effective, such therapies 
entail long term commitment in an intensive program with close supervision and are 
hardly sustainable in a clinical setting [4]. Even since the discovery of the obesity gene, 
agouti, in 1992, knowledge build-up in tracing cellular and molecular pathways 
underlying obesity and more recently, inter-organ crosstalk (liver, heart, brain, pancreas, 
skeletal muscle, kidney and vascular endothelium), has been essential for the 
development of pharmaceutical agents to reduce excess body adiposity and mitigate 
accompanying comorbidities [2, 9].  
Deterioration in the function of adipose tissue caused by obesity is strongly associated 
with the development of type II diabetes [2], which affects more than 370 million people 
worldwide [10]. Statistics on the global prevalence of type II diabetes report a rise from 
4.7% in 1980 to 8.5% in 2014, with an estimated of 1.5 million deaths in 2012 [11]. Due 
to the highly inflammatory state of adipose tissue caused by obesity, proinflammatory 
factors such as monocyte chemoattractant protein 1, MCP-1, tumor necrosis factor alpha, 
TNF-α and cytokines such as interleukin 1 beta, IL-1β are secreted which lead to increase 
in lipolysis and decrease in triglyceride synthesis [12]. High amounts of circulating free 
fatty acids (FFAs), that can no longer be stored in the already triglyceride-overloaded 
adipose tissue, accumulate in glucose-metabolizing tissues such as skeletal muscle, liver 
and pancreatic β-cells [13, 14] leading to the damage of the normal insulin secretion in 
response to glucose, an effect known as insulin resistance [10, 15]. Insulin resistance sets 
the physiology up for type II diabetes and adversely affects lipid metabolism [13]. 
Interventions that seek to address both obesity and type II diabetes must aim at mitigating 
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adipose tissue dysfunction [15] by managing inflammatory markers, insulin resistance 
and adipose hormone signaling [16].  Lowering the FFA levels acutely in diabetic 
patients with an anti-lipolytic drug, Acipimox, has shown evidence of improved insulin 
action on glucose uptake [17]. Antidiabetic agents such as peroxisome proliferator-
activated receptor-γ, PPARγ agonists and glucagon-like peptide 1 receptor (GLP1R) 
agonists have also displayed partial success in ameliorating adipose health [9]. Concisely, 
pharmacological and therapeutic mediation for obesity and type II diabetes must revolve 
around adipose tissue biology to improve metabolism, restore physiological hormone 
signaling and systemic energy homeostasis [18]. 
 
1.2 Regulators of energy: Adipose tissue 
Adipose tissue regulates a myriad of physiological process and plays a crucial role in 
ensuring that proper energy expenditure takes place in the body. There are two major 
types of adipose tissues in humans; white and brown [19].  
 
1.2.1 White Adipose Tissue 
White adipose tissue (WAT) was classically characterized as a passive organ, simply to 
dissipate excess calories or to release FFAs during high energy demands [9, 20].  
However, over the past two decades, emerging evidence elevated its status from a mere 
lipid sink to a highly active major endocrine organ, capable of secreting hormones and 
adipokines (Figure 1.1) including leptin and adiponectin [21, 22]. WAT is responsible for 
inflammation, mechanical organ protection and thermoregulation [23]. Triglycerides 
stored in WAT are in the form of unilocular droplets that occupies ~90% of the cell 
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volume [24]. Distribution of WAT is categorized by anatomical location of adipose 
depots; visceral and subcutaneous [25]. 
 
Figure.1.1: White adipocytes as an endocrine organ. Network of important 
adipokines and hormones regulated by white adipose tissue. Reprinted with 
permission from Elsevier [19]. 
 
The different locations and distribution can be attributed to variable functions where 
energy utilization between depots also differs greatly, according to body requirements. 
Priority of first line of mobilization of fat depots include subcutaneous, mesenteric 
followed by retroperitoneal when faced with energy restriction [26]. The main differences 
between visceral and subcutaneous fat behavior can be attributed to adipokine secretion, 
rates of lipolysis and triglyceride synthesis [27]. Disparate innervation and specific 
physiology with regards to circulation suggest different contributions of visceral and 
subcutaneous fat to the pathogenesis of dyslipidemia and other risks during weight gain. 
For example, visceral fat has been conventionally linked to hepatic insulin resistance in 
the case of excess abdominal mass [28], due to venous drainage of visceral fat that 
empties into the portal circulation, therefore exposing the liver to by-products of 
5 
 
adipokines [29]. Additionally, preadipocytes of different depot types express their 
respective gene signatures, along with distinct adipocyte behavior even after prolonged 
cultivation and passaging under similar conditions [27, 30]. While visceral fat 
transplanted into subcutaneous regions showed no improvements, placing subcutaneous 
fat into visceral fat regions demonstrated reduced adiposity and improved glucose 
homeostasis [31], signifying the potential protective benefits of subcutaneous fat in 
systemic metabolism and energy homeostasis [32].  
 
1.2.2 Brown Adipose Tissue 
1.2.2.1 History of BAT 
Apart from the commonly known white adipose tissue for lipid storage, there exists 
another type of adipose tissue; brown adipose tissue (BAT). BAT was first described in 
1551 as a thermogenic or heat-producing organ that is present specifically in mammals 
[33]. The heat production mechanism mediated by BAT, known as thermogenesis, has 
been well documented from research done in small rodents, such as rat, mouse and 
hamster [34]. BAT functions to keep small animals warm in cold environments, including 
newborn humans during the initial hours following birth [35]. In humans, studies in 
newborns identified the source of abundant brown adipose tissue in the region between 
the shoulder blades (interscapular), [36] which recedes in size, leaving scarce traces, or 
none, of it in adults. Fluorodeoxyglucose-PET (FDG-PET) functional imaging, a 
technique used to detect glucose-consuming tumors, revealed the surprising existence of 
several brown adipose distinct depots distributed in symmetrical locations in adults [33, 
37, 38]. Furthermore, these observed depots showed evidence of metabolically active 
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BAT and a remarkable uptake of glucose upon acute cold exposure (19 °C) [33, 37, 39, 
40]. By contrast, BAT depots were discovered to be undetectable in people that were kept 
warm [34]. The anatomical sites that were identified include anterior neck, 
supraclavicular, paravertebral, mediastinum, around the heart, infra-diaphragmatic and 
perirenal regions [41]. Interesting to add, BAT produces significantly lower levels of 
some hormones and cytokines that are abundantly produced by WAT such as resistin and 
angiotensin [35], making it capable of managing and buffering inflammatory 
environments created by obesity. Given the evidence of brown adipose tissue now 
validated to be present in human adults, coupled with its high latent metabolic activity 
and anti-inflammatory influence, BAT holds tremendous promise in research aimed at 
improving adipose tissue health in obese patients. 
 
1.2.2.2 UCP1 and Thermogenesis 
Cells of brown adipose tissue observed under microscope show a dense collection of 
mitochondria with a central nucleus and a multi-locular architecture of lipid droplets at 
sizes measuring between 38µm to 45µm, weighing a total mass of between 60 to 100g in 
humans [21, 33]. The most unique and valuable feature of brown adipose tissue lies in its 
ability to conduct thermogenesis and thus presents itself as a crucial site for heat 
production [42], most importantly for defending body temperature of newborns without 
shivering [43]. It was also found that cafeteria diets in rodents that cause overfeeding 
stimulate the expansion and activation of brown fat to restrain weight gain and obesity 
[44, 45], thus utilizing thermogenesis as a protection from diet-induced obesity [46], 
which suggests two types of mechanisms for thermogenesis: (1) thermoregulation and (2) 
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metabolically regulated thermogenesis [47]. Thermogenesis is made possible by the 
presence of the unique BAT protein of uncoupling protein-1 (UCP1) that is expressed on 
the inner membrane on the mitochondrion [42, 46, 47]. Highly innervated BAT responds 
to an external cold challenge with a sympathetic nervous system response mediated by 
the hypothalamus, by releasing the hormone norepinephrine (NE). Norepinephrine 
activates β3 adrenoceptor (β3-AR) and causes the catalyzed production of cyclic 
adenosine monophosphate (cAMP) and activation of cAMP-dependent protein kinase 
(PKA), leading to the transcription of UCP1 [43]. Endogenous lipolysis is triggered to 
generate free fatty acids that enter the mitochondria and bind to UCP1, thus activating it 
(Figure 1.2). Following which, UCP1 uncouples aerobic respiration and allows a rush of 
protons to enter the mitochondrial matrix from the inter-membrane space, thus disrupting 
the electrochemical proton gradient and generate significant heat, instead of adenosine 




Figure 1.2: UCP1 activation and thermogenesis stimulated by free fatty acids in 
BAT, beginning with norepinephrine (NE), resulting in lipolysis via the activation of 
hormone sensitive lipase (HSL), mitochondrial uncoupling and thermogenic 
respiration.  
 
At this point, ATP efficiency decreases due to the mitochondrial uncoupling [37], 
resulting in the increase in aerobic respiration and energy expenditure to maintain the 
proton gradient and ATP production. Central to the thermogenic function of BAT is the 
transcription of UCP1, which has been attributed to the p38 mitogen-activated protein 
kinase (MAPK) pathway. The three possible mechanisms of this pathway include: (1) 
nuclear factor activating transcription factor 2 (ATF2) phosphorylated by p38-MAPK 
which enhances the transcription of UCP1 via cAMP regulatory elements [48], (2) 
Zfp516, a zinc-finger protein, which has been shown to be upregulated by cold 
stimulation through cAMP response element binding protein CREB/ATF2 pathway, 
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interacts with  PRDM16, a brown adipose transcriptional co-factor, to activate UCP1 
transcription [49] and (3) phosphorylation of peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha, PGC1α that is bound to PPARγ and in turn UCP1 by the 
peroxisome proliferator response element [48]. Independently, PKA is described to be 
able to directly induce UCP1 transcription through CREB which binds to the CRE in the 
proximal promoter region of UCP1 gene [50]. The amount of heat produced in BAT 
relies mainly on the degree of activation of BAT sympathetic nerves, extent of 
subsequent NE release as well as intensity of binding of released NE to adrenergic 
receptors [51]. Maximum extent of uncoupling of BAT in adult humans with amounts 
measuring 40-50g is reported to be capable of producing 20% energy expenditure [47]. 
Thus, harnessing even a slice of this energy leads to beneficial outcomes in restoring 
energy balance in the body and maintaining body weight.  
 
1.2.2.3 Types of brown adipocytes: Classical brown and beige 
Along with the knowledge of BAT and its compelling metabolic significance, emerging 
evidence report the presence of UCP1-positive adipocytes, UCP1 protein capable of 
facilitating thermogenesis, in white adipose depots described as beige or brite (brown-in-
white) adipocytes [52]. Similar to characteristics of BAT, beige cells in mice have been 
described to possess high mitochondrial density, multilocular droplets and UCP1 for 
thermogenesis [42]. A host of factors including distinct gene signatures have reported 
brown and beige to arise from distinct cell types [53]. While the cellular origins of beige 
adipocytes have not been completely traced [54], it is hypothesized that they arise from 
brown adipocyte precursors present in WAT or by direct conversion of white adipocytes 
[55]. A major difference between brown and beige is observed in the expression of 
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thermogenic genes in BAT at unstimulated conditions; beige adipocytes express them 
only when stimulated under the influence of strong activators (β-adrenergic receptor or 
PPARγ agonist like thiazolidinediones) [56]. Since beige adipocytes possess both brown 
and white traits, they are described to respond bi-directionally between white and brown 
adipose characteristics depending on the stimuli. In acute cold phases, white adipocytes 
with BAT-containing precursors undergo browning to become beige and function as 
brown adipocytes and conversely, in warm phases, beige adipocytes lose their brown 
capabilities and revert to white adipose [27, 28]. This browning effect is reversible and 
dependent on external environmental cues [56]. Heterogeneous beige cell populations are 
distributed in supraclavicular, perirenal, paravertebral regions and mainly in the 
subcutaneous WAT depots in humans [54].  In addition to this, bone marrow derived 
MSCs were differentiated into brown adipocytes and whilst the brown marker ZIC1 was 
noted to have been expressed, beige markers also showed up in expression, pointing to 
the fact that bm MSCs may contain subpopulations of brown progenitor cells, brown 
inducible adipocytes amidst a white adipocyte population [57].  
Beige adipocytes possess UCP1 expression with the corresponding ability to perform 
uncoupled respiration, that match the response of stimulated brown adipocytes [52], 
uncovering a trove of UCP1-expressing adipocytes for exploitation. Recruitment of BAT 
activity in the form of beige cells offers overlapping features of beige and brown 
adipocytes which provide a wider therapeutic scope for establishing thermogenic 
mechanism. Enhanced beige and brown fat function holds strong promise of tackling 




1.2.2.4 Cellular models of human brown adipose 
Crucial to the understanding of the differentiation and function of BAT are human 
adipocyte cellular models which can be extrapolated into therapeutic strategies in 
humans. Well-established studies in gene expression and cellular mechanisms were 
mainly done in small mammals such as rodents and mice [58], however, little is known 
about the molecular characterization in human BAT [59]  In vivo differences between 
mice and humans in terms of quantity of brown adipose tissue, anatomical localization 
and “brite” adipocyte formation highlight the importance of working on human models 
[60].  Collectively, there are a number of human cellular models available: (1) 
immortalized cell lines isolated from BAT, (2) primary culture derived from human 
adipose tissue (3) brown adipocytes differentiated from human pluripotent stem cells and 
(4) human stem cell sources [60].  Although there exists a human BAT cell line PAZ6 
derived from infants [61, 62], immortalized cell lines still lack certain BAT functional 
features [60] and may also lead to loss of gene expression over time, as reported in 
immortalized SVF derived from subcutaneous depot in mice where loss of gene 
expressions Asc-1 and PAT2 were discovered [63]. 
Human stem cell with adipose progenitors offer unrivalled opportunities to study 
governing signaling networks of adipose differentiation, modulation and function [42], 
resembling close to in-vivo environments. Tissue engineering introduces cell source 
options to build brown differentiation models including (a) stromal vascular fraction 
(SVF) from adipose tissue as a rich and diverse source of pre-adipocytes and 
stromal/stem cells. [64] where, stromal vascular fraction (SVF) is useful for direct culture 
and expansion of an adherent population [65]  (b) human multipotent adipose derived 
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stem cells (hMADs) and (c) multi potent bone marrow mesenchymal stem cells (bm 
MSC) [66].  With the exception of interscapular BAT which is nestled separately by 
connective tissue from subcutaneous WAT [67], the fact remains that fat distribution of 
distinct adipose types (brown and white) are unconfined and mixed within typical fat 
anatomical locations. Knowledge of lineage commitment of progenitor cells extracted 
from different sources is advantageous in the study of brown adipocytes. 
Subcutaneous-SVF (SC-SVF) 
Subcutaneous-SVF is derived from the layer between the fascia and muscle[68], 
comprising pre-adipocytes with the ability to differentiate into white and beige 
adipocytes[69]. Brown adipocyte precursors contained in inguinal WAT depot from 
mice, give rise to prominent UCP1-positive adipocytes [53, 68]. Additionally, human 
abdominal subcutaneous WAT has been shown to express BAT genes, UCP1 in 
particular [70]. Thus, brown differentiation models based on human subcutaneous-SVF 
can prove to be worthwhile. 
Bone marrow-derived MSCs (bm MSCs) 
As a heterogeneous stem cell population, adult derived mesenchymal stem cells have the 
potential to differentiate into multiple cell types like chrondocytes, adipocytes and 
osteoblasts [66]. Bone marrow derived mesenchymal stem cells have the ability to 
differentiate into both white and brown adipocytes[57]. Specifically, macromolecular 
crowding, together with a standard brown differentiation protocol, enhances the 
differentiation of bm MSCs into brown adipocytes, with surpassing expression of UCP1 




Human multipotent adipose derived stem cells (hMADs) 
Typically extracted from young, pediatric donors, hMADs have been used in several 
studies to successfully differentiate into brown adipocytes [66]. As a multipotent source 
of progenitor cells, it has the ability to differentiate into different lineages such as 
adipocytes and osteoblasts [72]. Under various activators such as the hormone T3 and β-
AR agonist [73], hMADs express UCP1 and various factors such as CIDEA, and CPT1B 
[21] that give rise to mitochondrial biogenesis and uncoupling [66], thus making it a 
suitable model to study brown differentiation and function in humans.  
 
1.2.2.5 Activating BAT 
Knowledge of the availability of beige fat, distributed in the various anatomical regions, 
adds a new dimension to the strategies employable to activate BAT function. Due to its 
powerful significance on systemic metabolism, strategies to fully exploit thermogenesis 
center around advancing the volume of current canonical BAT depots and as well as 
browning of WAT to induce functional brown adipocytes [74]. The most extensively 
studied strategy to activate BAT remains to be cold exposure [74], due to its sympathetic 
nervous system (SNS) innervation [75]. Pharmacological compounds to target receptors 
on the SNS pathway have also been developed to initiate BAT function and they include 
isoprenaline, ephedrine [76] and capsinoids which targets the transient receptor potential 
vanilloid 1 (TRPV1), and carry an indirect, downstream SNS activation [75]. Activation 
of the TRP-BAT axis through non-calorific food ingredients such as ginger, black pepper, 
mustard, cinnamon and green tea also elicits an SNS response for energy expenditure 
[77]. Use of a specific β3-AR agonist, mirabegron that targeted human BAT specifically, 
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successfully activated thermogenesis and increased resting metabolic rate, however, 
simultaneously induced tachycardia(abnormal heart rate) due to binding to β1-AR [78]. 
Undesirable effects arising from such specific targeting remains to be reconciled and 
highlights the danger of SNS activation. Apart from SNS targeting, brown and beige 
carry their own molecular signatures which can be activated, either together with SNS 
signaling or independent of it. Current non-adrenergic pathways involve the introduction 
of pharmacological compounds, ranging from vitamins such as Vitamin A derivatives to 
bile acids, FGF21 (fibroblast growth factor 21), thyroid hormones, irisin, natriuretic 
peptides, vascular endothelial growth factor (VEGF) and bone morphogenetic proteins 
(BMPs) [51, 74, 75]. Development of such drug targets requires us to study adipocyte 
biology at genetic and protein levels to pick out cell surface markers that may be 
compatible in activating BAT function. 
 
1.3 Solute carrier genes 
1.3.1 Gatekeepers for cell activities 
Efficient cellular uptake of important molecules and compounds such as sugars, amino 
acids, vitamins, nucleotides, nucleosides, ions, gases, co-factors are crucial for cell 
function [79]. Membrane bound transporter proteins that control the movement of such 
substrates, are divided into numerous categories, namely ATP powered pumps, ABC 
transporter, ion and water channels and solute carriers (SLCs) (Figure1.4) [80]. Solute 
carrier genes greatly outnumber the rest of the classes of membrane bound transporter 





Figure 1.3: Types of membrane bound transporter proteins. A: Solute carriers and 
B: Other types of transport proteins outside of the SLC family. Reprinted under 
Creative Commons License CC-BY 4.0. Available from:        
http://dx.doi.org/10.1016/j.mam.2012.12.009 [82] 
 
Solute carriers play the role of gatekeepers that regulate substrates between the cell’s 
internal physiology and its immediate environment, and can be localized on various 
components of the cell including the cell membrane and intracellular sites like 
mitochondria and vesicular membranes [83]. SLCs’ mode of transport is independent of 
ATP and described as facilitative or passive, where substrates are transported along the 
electrochemical gradient and secondary active transport (exchangers), which can be 
categorized into two groups; antiporters and symporters [80]. Each family is grouped 




Figure 1.4: Cluster map showing intertwined functions according to substrate type. 
Nodes in grey represent families yet to be characterized. Reprinted with permission 
from John Wiley & Sons [84]. 
 
The type of substrate it transports gives us clues to its physiological roles and functions. 
SLCs within the same family may transport similar substrates with different specificity 
[85]. For example, the family of SLC22 include SLC22A4 and SLC22A5 where both 
transport L-carnitine with different affinities, low in SLC22A4 and highly specific in 
SLC22A5 [86]. Whereas, some SLCs display overlapping substrate transport between 
families [85], depending on localization of the SLC. OCT1, or SLC22A1, has been 
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reported to be a high capacity thiamine transporter expressed in hepatocytes, while 
transporters SLC19A2 and SLC19A3 are also known to transport thiamine, in intestinal 
cells [87].  
 
1.3.2 Therapeutic pharmacological targets 
Knowledge of the functional mechanism of SLCs is especially advantageous in the fields 
of pharmacology and drug delivery [83], since SLCs serve high pharmaceutical relevance 
as drug targets or as a mechanism for drug delivery to cells and tissue systems [83, 88]. 
Amongst the highly-targeted solute carriers include the SLC6 family of neurotransmitters 
for neuropsychiatric drugs, SLC5 family of glucose transporters for diabetes as well as 
the cation-Cl co-transporters from SLC12 family for diuretic drugs [82, 88]. The design 
of the drug accounts for the choice of inhibition or stimulation of the SLC transporter 
activity [87] to mediate action on excess or deficiency of the substrate. SLCs, thus, 
inherit the responsibility of regulating the absorption, distribution, metabolism, and 
elimination (ADME) of these substrates [84]. The uricosuric drug, Probenecid, has been 
used as treatment for gout (crystallization of uric acid in joints) by the inhibition of 
organic anion transporter SLC22A6 to prevent the reabsorption of uric acid in the 
kidneys. [79]  
 
1.3.3 Relevance of SLCs and BAT 
Interestingly, the discovery of BAT shares a common history with SLCs, in which the 
visualization of its presence was through the uptake of glucose tracer (18FDG) by the 
glucose transporter GLUT-4 also known as SLC2A4. Despite high relevance to 
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physiological insights in health and disease, SLCs have not been given much attention 
with a mere 12 SLCs being targets of FDA approved drugs [83]. Notwithstanding the fact 
that the exclusive protein found in BAT;UCP1 happens to be SLC25A7, studies to 
characterize cell surface markers in the different types of adipocytes has led to the recent 
discovery of ASC-1(SLC7A10) as a marker distinguishing WAT and BAT [89] and nails 
the importance of transporters as candidates for functional markers for BAT.  
 
1.4 Hypotheses 
What has been described thus far is the availability of the therapeutic option of brown 
adipose tissue to combat metabolic disorders such as obesity and diabetes. Many studies 
have explored the genetic machinery in BAT that can play a role in alleviating the effects 
caused by both diseases. The aim here is to study the expression of SLCs to identify and 
discriminately target brown adipocytes for therapeutic purposes. As such, the hypotheses 
are described in two parts: 
1) Mature adipocytes contain SLC markers that distinctly mark for white and brown 
adipocytes and are pharmacological targets for specific non-adrenergic regulation of 
BAT 
2) Substrates transported by brown adipose specific-SLCs enhance brown adipose 
differentiation and function that elucidate key signaling BAT pathways and allow for 







Chapter 2: Materials and Methods 
2.1 Stem Cell Culture 
Adult human bone marrow mesenchymal stem cells (bm MSC) were obtained 
commercially (Lonza/Cambrex Bioscience, PT-2501, Walkersville, MD, USA). 
Progenitor cells from the abdominal subcutaneous and omental stromal vascular fraction 
(SC-SVF and OM-SVF) were obtained from donors who underwent bariatric surgery as a 
collaboration with Dr. Sue-Anne Toh. All subjects had provided informed consent and 
were patients from the Centre for obesity and metabolic surgery, National University 
Health System (NUHS, Singapore). Ethics approval was obtained from the National 
Healthcare Group Domain Specific Review Board (Singapore) and the procedures were 
carried out in accordance with the approved guidelines. The human multipotent adipose 
derived stem cells (hMADs), derived from the pre-pubic fat pad of infants, were a kind 
gift from Dr. Ez-Zoubir Amri [90]. All cells were grown in DMEM supplemented with 
GlutaMAXTM and 10% FBS (10567 and 10270 Life Technologies, Carlsbad, CA, USA). 
Table 2.1 reflects the details of the stem cell source with its respective lot number used 
throughout the duration of the study. 
.Stem Cell sources Lot Number 
bm MSC 
Bone marrow 






















Table 2.1: Stem cell sources and their respective lot numbers 
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2.2 Adipogenic induction of progenitor cells 
Unless otherwise stated, stem cells from each source were seeded at an initial density of 
10,500 cells/cm2. Adipogenic differentiation was introduced when the cells reached 
confluence. The cells underwent a four-day induction phase twice with a three-day 
maintenance phase in between. Non-induced controls were maintained with basal media 
alone on the same schedule. The basal media used in the differentiation process 
composed of high glucose DMEM supplemented with GlutaMAXTM and 10% FBS 
(10569, 10270, Life Technologies). 
For white adipocyte induction, the white induction (iw) cocktail consisted of 0.5 mM 3-
isobutyl-1methylxanthine (IBMX), 0.2 mM indomethacin, 1 μM dexamethasone, 
10 μg/ml insulin (I5879, I7378, D4902, 91077C, Sigma-Aldrich, St-Louis, MO, USA). 
Basal media was used during the maintenance phase. When ascorbic acid was used 
(iw+AA), 100µM L-Ascorbic Acid (AA) (019-12063, Wako, Japan) was added during 
the induction and maintenance phases. Where stated, 125 ng/ml bone morphogenetic 
protein 4 (BMP4) (314-BP, R&D Systems, Minneapolis, MN, USA) and 1 μM 
rosiglitazone (ALX-350-125, Enzo Life Sciences Inc., Farmingdale, NY, USA) were 
used as a pre-treatment (three days prior to the first induction), or during the induction 
phases. 
For brown adipocyte induction, cells were pre-treated with 125 ng/ml bone 
morphogenetic protein 7 (BMP7) (354-BP, R&D Systems) three days prior to first 
induction. The brown induction (ib) cocktail consisted of 0.5 mM IBMX, 1 μM 
dexamethasone, 10 μg/ml insulin, 1 nM triiodothyronine (T3) (T5516, Sigma-Aldrich) 
and 1 μM rosiglitazone. Basal media with BMP7 was used during the maintenance phase. 
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For induction conditions requiring macromolecular crowding (MMC), the media was 
supplemented with a mixture of FicollTM70 at 37.5 mg/ml and FicollTM400 at 25 mg/ml 
(17-0310, 17-0300, GE Healthcare, Bio-sciences AB, Uppsala, Sweden), throughout the 
pre-treatment and differentiation period. Media was sterile ﬁltered with a 0.22mm syringe 
ﬁlter (16532, Satorius Stedim Biotech GmbH, Goettingen, Germany) before use. Where 
stated, carnitine (C0283, Sigma-Aldrich) and thiamine hydrochloride (T1270, Sigma-
Aldrich) were used separately as an additional growth factor together with the ib MMC 
protocol in differentiating bm MSC into brown adipocytes. 
 
2.3 Quantitative Polymerase Chain Reaction 
Total RNA was extracted using Trizol (15596018, Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA) and RNA yield was determined on the NanoDrop ND-1000 
spectrophotometer (Thermo Fisher Scientific). Subsequently, total RNA was reverse-
transcribed into cDNA. Real time quantitative PCR using Maxima™ SYBR Green/ROX 
qPCR Master Mix (K0222, Thermo Fisher Scientific) was performed for 35 cycles. 
Relative gene expression levels were determined using the ΔΔ-Ct method. Results were 
normalized to TATA-box binding protein (TBP). All primer sequences used are given in 
Table 2.2.  




F: 5’ -  CTGGAATAG CGG CGTGCTT – 3’ 
[40] 
R: 5’ – AATAACACTGGACGTCGGGC – 3’ 
Leptin NM_000230.2 
F: 5’ - TTTGGCCCTATCTTTTCTATGTCC – 3’ 
[91] 
R: 5’ - TGGAGGAGACTGACTGCGTG – 3’ 
FABP4 NM_001442.2 
F: 5’ – TGTGCAGAAATGGGATGGAAA – 3’ 
[92] 
R: 5’ - CAACGTCCCTTG GCTTATGCT – 3’ 
TBP NM_003194.4 
F: 5’ - CACGAACCACGG CACTGATT – 3’ 




F: 5’ – ACAGCAGGGGCATTAGTTTC – 3’ 
[93] 
R: 5’ – CAGCGTCTTTGACTGGATATTC – 3’ 
SLC5A3 NM_006933.6 
F: 5’ – GCTACGAGCTGGCTTTAATCCT – 3’ 
[94] 
R: 5’ – TTACTCAGGTGCTGGAGGAGAA – 3’ 
SLC7A10 NM_019849.2 
F: 5’-GTGGCGCTCAAGAAGGAGAT -3’ 
[63] 






F: 5’ TGCTGGTGGTGGCGTTTATTCA – 3’ 
[96] 
R: 5’ TGGAAGTTGGCGATGTCCTCTT – 3’ 
SLC19A3 NM_025243.3 
F: 5’ – CTGGCTCTGGTGGTCTTCTC – 3’ 
[97] 
R: 5’ –AGGCATAGCGTTCCACATTC – 3’ 
SLC22A5 NM_003060.3 
F: 5’ - CCAAAGCCAATGGGATTGTT – 3’ 
[98] 




F: 5’ – CGAGGCCACCGGAGC – 3’ 
[99] 
R: 5’ – CACAAAGCACACTCAGTGCC – 3’ 
SLC25A11 NM_003562.4 
F: 5’ – TCCAAGCAGTTCTTACTGGAC – 3’ 
[100] 
R: 5’ – CGTAGCGGACAACTTTGAACA – 3’ 
SLC25A13 NM_014251.2 
F: 5’ – AGATGGTTCGGTCCCACTTGCA – 3’ 
[101] 
R: 5’ – ACCAGTGGTGATTTCTCCTGCC – 3’ 
SLC29A4 NM_153247.2 
F: 5’ – GGGACCTCCATCGTGTTTGA – 3’ 
[102] 
R: 5’ – CTCCACCAGGACGTTGTTCA – 3’ 
SLC39A14 NM_015359.4 
F: 5´ - GCTTATGGAGAACCACCCCT- 3´ 
[103] 







Table 2.2: All primer sequences that were used in this study. 
F = Forward primer sequence. R = Reverse primer sequence 
 
2.4 Western Blot 
For experiments with forskolin stimulation, cultures were incubated with high glucose 
DMEM supplemented with GlutaMAXTM and 10% FBS for a day before stimulation with 
10 μM forskolin (F6886, Sigma-Aldrich) or DMSO (vehicle control) for 16 hours. 
Sample protein extracts were obtained from cell monolayers using RIPA buffer, were 
separated using SDS-PAGE under reducing conditions and then transferred onto a 
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Membrane was washed in 
TBST pH 8 (20 mM Tris-base–150 mM NaCl–0.05%Tween-20) for five minutes before 
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blocking with 5% fatty acid-free BSA for 1 hour at room temperature (RT). For immune-
detection, primary antibodies used were: anti-mouse UCP1 (dilution 1:1000, mab6158, 
R&D Systems, Minneapolis, MN, USA), anti-rabbit SLC22A5 and anti-rabbit SLC19A3 
(dilution 1:1000, 16331-1-AP, 13407-1-AP,  Proteintech Group, Inc, Rosemont, USA), 
monoclonal mouse anti-α tubulin (1:1500, T6074, Sigma Aldrich) as a loading control. 
Bound primary antibodies were detected with goat anti-mouse HRP (P0447, Dako) and 
goat anti-rabbit HRP (P0448, Dako, Glostrup, Denmark) diluted 1:3000 in 3% fatty acid-
free BSA for 1 hour at RT. Chemiluminescence was captured with a SuperSignal West 
Femto Maximum Sensitivity Substrate Chemiluminescent kit (34096, Thermo Fisher 
Scientific) and ChemiDoc MP Imaging System (Bio-Rad). 
 
2.5 Mitochondrial oxygen consumption 
Cells were seeded at a density of 8000 cells/well in XF24e cell culture plates (100850-
001, Seahorse Bioscience, Chicopee, MA, USA). At the end of the differentiation 
process, cells were first washed with HBSS(14175-095, Life Technologies) and then 
incubated in 500 μl of XF assay medium (Seahorse Bioscience) for  approximately 
30 min at 37 °C in a warming station at atmospheric conditions before loading into the 
Seahorse XF24e analyser (Seahorse Bioscience) to measure the oxygen consumption rate 
(OCR). For thermogenic stimulation, 10 μM forskolin (F6886, Sigma-Aldrich) was used. 
Unstimulated cultures were incubated for the same period with the addition of an equal 
amount of DMSO as vehicle control. 10 μM forskolin (or DMSO as vehicle control) was 
added for 100 min. Oligomycin (2 μM, 75351, Sigma-Aldrich), FCCP (0.6 μM, C2920, 
Sigma-Aldrich), and Rotenone (2 μM, R8875, Sigma-Aldrich) together with Antimycin 
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A (2 μM, A8674, Sigma-Aldrich) were then injected sequentially to identify the different 
components contributing to total oxygen consumption. Oligomycin and FCCP provided 
information on uncoupled and maximal capacity for respiration respectively. Rotenone 
and Antimycin A were used to inhibit complex-1 and complex-3 dependent respiration in 
the electron transport chain so as to compute non-mitochondrial respiration, to be 
subtracted during the analysis. Where stated, 0.1 µM Carnitine (C0283, Sigma-Aldrich) 
was also used as a thermogenic stimulant. 
 
2.6 Cell lysis and Picogreen Assay  
Cells in the XF 24e cell culture plates were washed with PBS. 100µL of Proteinase K 
solution (Proteinase K powder (P2308, Sigma Aldrich) in 10mM Tris-HCl pH 8.5-9.0 
with 40% glycerol in 10mM Tris-HCl pH 8.5, 1mM EDTA, 0.1%(v/v) Triton X-100 at 
10x dilution) was added to each well for cell extraction and incubated at 60 °C overnight. 
Next, tubes were placed in -80 °C as the picogreen assay was prepared. Standard buffers 
of varying concentrations were made for calibration purposes using the Quant-iT 
Picogreen dsDNA Assay kit (P7589, Life Technologies). Samples laced with fluorescent 
Picogreen tracker were excited at 480 nm and the fluorescence emission intensity was 
measured at 520 nm using the Pherastar fluorescence microplate reader (BMG Labtech, 
Ortenberg, Germany) and using Pherastar-Data Analysis and MARS softwares. With the 
fluorescence emission intensity data, a DNA standard curve was plotted with 
fluorescence signal as a function of DNA concentration (ng/ml). DNA quantification is 
then calculated accordingly to be normalized against the oxygen consumption rates data 
(See section 2.4) 
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2.7 Quantification of Lipid Droplet 
Cells were washed with PBS, fixed in 4% formaldehyde for 30 min at RT, then co-
stained for 30 min with 5 μg/ml Nile Red (N3013, Sigma-Aldrich) for lipid droplets and 
0.5 μg/ml of 4′,6-diamidino-2-phenylindole (DAPI) (D3571, Life Technologies) for cell 
nucleus. Nine image sites per well were acquired using 2× magnification with a 
coolSNAP HQ camera attached to a Nikon TE2000 microscope (Nikon Instruments), 
stored, and analyzed using the Metamorph Imaging System Software 6.3v3 (Molecular 
Devices). Nile Red was viewed under a rhodamine filter [Ex572 nm/Em630 nm], while 
DAPI fluorescence was assessed with a DAPI filter [Ex350 nm/Em465 nm]. The Cell 
Count module was used for cell enumeration, while the Integrated Morphometry Analysis 
module was used to evaluate the area of fluorescent Nile Red staining. A specified 
threshold defined by fluorescent intensity below a defined pixel value was subtracted to 
eliminate background area. Extent of adipogenic differentiation was quantified by area of 
Nile Red fluorescence normalized to nuclei count leading to total lipid droplet area per 
well/number of cells. (μm2/nuclei). 
 
2.8 Illumina Bead Chip microarray analysis 
The Illumina Bead Chip was kindly provided by Dr. Lawrence Stanton from the Genome 
Institute of Singapore (GIS) A*Star. Purity of RNA determined by Bioanalyzer, 
microarray and statistical analysis were kindly done by Dr. Sathiyanathan Padmapriya 
from GIS. Cells were seeded at a density of 10,500 cells/cm2. Adipogenic induction was 
introduced after confluence was achieved as described in Section 2.2. Total RNA was 
extracted using Trizol (15596018, Invitrogen, Thermo Fisher Scientific) and on-column 
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digestion of DNA was performed during the RNA isolation and purification step using 
the RNase-Free DNase Set (79254, QIAGEN®,). RNA yield was determined on the 
NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific). RNA quality was 
confirmed with the Agilent RNA 6000 pico kit on the Agilent 2100 Bioanalyzer system 
(Agilent Technologies, Santa Clara, CA, USA). RNA harvested from the samples was 
then amplified with the TotalPrep RNA amplification kit according to manufacturer’s 
protocol (Ambion). The resulting purified biotin-labelled complementary RNA (cRNA) 
was quantified and 500 ng cRNA was applied to the HumanHT-12 v4 expression 
beadchip (Illumina, San Diego, CA, USA) following the direct hybridization instructions. 
Cy3 conjugated to streptavidin was used to label the hybridized cRNA. The chip was 
scanned on the BeadArray Reader and imaged with the BeadScan software (both from 
Illumina). The raw data were background subtracted and converted into expression 
profile by GenomeStudio (Illumina), and further analyzed with GeneSpring v12.5 
(Agilent Technologies). The data were normalized to 75th percentile per chip and to 
median per gene. Genes with differential expression were selected by averaging the 
replicates and pairwise analysis was done with two-way ANOVA and hierarchical 
clustering.  Statistical significance according to t-test paired/ unpaired was set as p ≤ 0.05 
and data were filtered using fold change cut-offs ≥ 1.5. 
Only solute carrier genes were examined amongst all differentially expressed genes. In 
the first step of the analysis, solute carrier genes that were differentially expressed in 
brown and white adipocytes were selected for the next phase of filtering. In the next step, 
the SLC genes that were selected in step 1 were further filtered according to their 
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differential expressions at differentiation time point = Week 2. The final list comprised 
two groups of brown and white associated SLC genes. 
 
2.9 Statistical analysis 
Unless otherwise stated, all assays were performed in triplicates, and results were 
reported as mean ± SEM. Statistical analysis used were One way ANOVA statistical 
analysis, followed by Tukey–Kramer Multiple-Comparisons Test. *p < 0.05, **p < 0.01, 
and ***p < 0.001. Graphpad Prism 7 (Graphpad Software) was used to carry out the 



















Chapter 3: Results 
In order to mine for SLCs in human BAT, I began by first establishing a primary adipose 
cell culture system that was well-characterized in phenotype and functionality. Brown 
phenotype was verified by characterizing UCP1 mRNA and protein expression as well as 
observation of multi-locular lipid accumulation while functionality was determined by 
the measurement of mitochondrial respiration. In this model, brown adipocytes were 
differentiated from three stem cell sources; (a) human multipotent adipose derived stem 
cells (hMADs), (b) subcutaneous stromal vascular fraction (SC-SVF) and (c) bone 
marrow mesenchymal stem cells (bm MSC). The brown induction protocol that was used 
was adapted from Lee et. al and denoted as ib or ib mmc accordingly, depending on 
whether macromolecular crowding (MMC) was added [57]. To be able to distinguish and 
determine SLCs as cell surface markers for brown adipocytes, white differentiated 
adipocytes had to also be included as a control. 
Therefore, the first step was to establish a control in the form of white adipocytes. As 
described previously (Section 1.2.1), white adipose tissue depots are of two main types; 
subcutaneous and visceral including omental, mesenteric, mediastinal and epicardial [69, 
105]. Intrinsic characteristics and anatomical location differences of subcutaneous white 
adipose tissue lead to its’ bifurcated ability to differentiate into brite (brown-in-white), 
also known as beige, or mature white adipocytes, giving rise to a mixed population 
[69].Visceral fat, on the other hand, is described to possess homogeneous distribution of 
large, unilocular adipocytes [106]  that is consistent with the description of mature white 




3.1 Ascorbic Acid enhances white adipogenesis 
Standard white induction protocol, denoted as iw, comprising IBMX, dexamethasone, 
insulin and indomethacin (Section 2.2), was used to differentiate progenitor cells from 
OM-SVF to white adipocytes. Phenotypic characterization of white adipocytes was 
correlated to mRNA expression of the well-known white adipocyte marker, leptin [19, 
107] and adipose lipid maturity marker; FABP4. 
 
Figure 3.1: Omental-SVF exhibits poor white phenotype. OM-SVF was differentiated 
to white adipocytes using the white induction protocol (iw). qPCR analysis of leptin, 
UCP1 and FABP4 was performed. Data is expressed as mean ± SEM. ns = not 
significant; *p < 0.05; **p < 0.01; ***p < 0.001. N = 3 
 
Confounding expressions of UCP1 and leptin observed in Figure 3.1 imply that the 
phenotype was indistinct to either white or brown. Commitment of white phenotype in 
omental-SVF seemed to be limited as reflected by low leptin expression levels. 
Consequently, the next goal was to fine tune the induction protocol to boost leptin mRNA 
levels, while maintaining low levels of UCP1, by the supplementation of ingredients 





Bone Morphogenetic proteins (BMP), belonging to the growth factor β-superfamily, have 
the potent ability to drive adipogenesis [108]. Specifically, BMP4 has been singled out to 
be a regulator involved in white adipogenesis [109, 110]. Rosiglitazone, a compound 
from the class of thiazolidinediones (TZD), is known to be a PPARγ agonist that 
accelerates the process of adipogenesis of pre-adipocytes in vitro. It’s mechanism of 
action involves binding to PPARγ to stimulate insulin sensitivity in the adipocytes [108, 
111]. Rosiglitazone has also been demonstrated to direct differentiation of human 
mesenchymal stem cells into adipocytes rather than osteoblasts [112]. As a whole, 
rosiglitazone presents as a useful pro-adipogenic agent to be used especially in cells that 
desist differentiation [108].  Ascorbic acid (AA) has been reported in numerous 
studies[113] to enhance lipid accumulation in bone marrow mesenchymal stromal cells in 
rats [114]  as well as 3T3-L1 murine cells [115, 116]. Macromolecular crowding was also 
considered to ascertain if it endows the cell with the necessary environment for white 
phenotypic commitment as well, just as it has been proven to enhance the expression of 
UCP1 in brown differentiated bone marrow derived MSCs and subcutaneous SVF [57]. 
Therefore, a list of induction growth conditions was designed with various permutations 
of the three additional growth factors of BMP4, Rosiglitazone and AA as well as 
















   *pre-treatment only 
Table 3.1: Combinations of additional induction growth ingredients of rosiglitazone, 


















Omental-SVF from two different donors were used for this set of induction growth 
conditions. 
 
Figure 3.2: Ascorbic Acid enhances leptin expression and suppresses UCP1 
expression. OM-SVF from two donors were differentiated to white adipocytes using the 
white induction conditions as reflected in Table 3.1 qPCR analysis of leptin, UCP1 and 
FABP4 was performed. Data is expressed as mean ± SEM. ns = not significant; *p < 0.05; 






























30.88 33.83 32.98 32.82 33.89 32.47 30.65 30.96 
31.8 31.6 30.53 32.9 33.9 33.65 30.72 31.44 
32.38 33.76 31.03 31.88 33.78 33.31 30.81 31.83 














28.68 23.56 22.52 21.43 20.14 24.47 23.99 25.57 
30.04 23.4 21.86 20.71 20.65 24.69 24.73 24.7 
32.2 20.83 22.02 21.16 20.98 23.99 24.73 23.3 














30.51 29.31 30.42 27.24 29.71 28.19 28.78 28.89 
29.89 28.45 29.76 29.96 29.33 28.93 28.43 28.86 
29.33 28.28 29.86 26.85 30.62 28.75 28.01 29.37 














27.53 17.48 16.14 16.52 15.52 18.46 16.76 16.96 
27.64 17.39 16.4 16.68 15.46 18.74 16.88 16.72 
27.86 16.79 16.4 16.29 15.5 18.42 16.13 16.54 
Table 3.2: Raw Ct values from qPCR analysis of leptin and FABP4 for both 
omental-SVF donors. qPCR analysis of all conditions for each gene was done in 
triplicates. 
 
Variable outcomes of leptin expression across all induction conditions between both 
donors as displayed in Figure 3.2 with low FABP4 expression, as seen from the Ct values 
in Table 3.2 suggested a deficiency in the differentiation capacity. Ct values for leptin in 
both donors showed no discernible differences between undifferentiated and 
differentiated cells. Ascorbic Acid in donor P#078 was noted to have caused a significant 
upregulation in leptin expression.  
As a visceral WAT depot which has a high likelihood of being affected by the metabolic 
syndrome, OM-SVF carries the risk of being exposed to undesired and anti-inflammatory 
secretions [117] than subcutaneous which could affect the quality of pre-adipocytes 
[118].  Several studies have shown poorer differentiation capacity of omental pre-
adipocytes, smaller adipocyte size as well as slower adipogenic proliferation rates 
extracted from obese individuals [64, 118, 119], when compared to abdominal 
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subcutaneous pre-adipocytes.Leptin production was also found to be higher in 
subcutaneous adipocytes than in omental [120]. 
As a result, the choice of stem cell source to differentiate white adipocytes from was 
modified to subcutaneous SVF rather than omental SVF, despite subcutaneous SVF’s 
dual ability to form beige (UCP1-positive) and white adipocytes.  
 
 
Figure 3.3: White differentiated SC-SVF show eight-fold increase in leptin 
expression. Subcutaneous-SVF was differentiated according to the induction conditions 
listed in table 3.1. qPCR analysis of leptin, UCP1 and FABP4 was performed. Data is 
expressed as mean ± SEM. ns = not significant; *p < 0.05; **p < 0.01; ***p < 0.001. 
N = 3 
 
In Figure 3.3, leptin expression was at least eight-fold higher in iw, iw+AA, 
iw+rosiglizatone+BMP4* and iw+rosiglizatone+BMP4*+MMC as compared to that in 
omental-SVF (Figure 3.2). It can be seen that macromolecular crowding (MMC) drove 
differentiation to a brown phenotype and suppressed leptin expression instead. FABP4 
expression was observed as comparable across all conditions and indicated enhanced 
degree of differentiation as compared to omental-SVF (20 fold higher). 
In order to eliminate any donor variation effect as observed in Figure 3.2, subcutaneous-
SVF and omental-SVF from the same donor were differentiated to white adipocytes 
according to the different conditions as shown in Table 3.1, to verify the degree of 
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phenotypic and differentiation commitment of both depots. In the next section, the 
comparisons between leptin expressions, adipogenic conversion efficiency and 
























3.2 SC-SVF has a superior adipogenic differentiation capacity compared to OM-
SVF 
General observations of higher leptin and FABP4 expressions in SC-SVF were 
immediately discernible from Figure 3.4. 
 
Figure 3.4: Superior Leptin and FABP4 expressions of SC-SVF over OM-SVF. 
Visceral (OM) and subcutaneous (SC) SVF from the same donor were differentiated to 
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white adipocytes under different induction conditions as reflected in Table 3.1. qPCR 
analysis of leptin, UCP1 and FABP4 was performed Data is expressed as mean ± SEM. 
ns = not significant; *p < 0.05; **p < 0.01; ***p < 0.001. N = 3 
 
Leptin expression across all conditions in SC-SVF was nine-fold higher than OM-SVF 
with an apparent peak under induction condition iw+AA, that was also picked out in 
Figure 3.2 and 3.3 for white differentiation. Similarly, FABP4 expression reflected a 10-
fold higher adipogenic capacity in SC-SVF than OM-SVF. This higher adipogenic 
capacity was also corroborated by the quantification of area of lipid accumulation 
normalized to cell count in Figure 3.5 below as well as visualization of lipid droplet 
accumulation between both depots in Figure 3.6. 
 
Figure 3.5: White differentiated OM-SVF and SC-SVF from the same donor show 
two-fold higher adipogenic conversion efficiency in SC-SVF. Both SC-SVF and OM-
SVF were differentiated under white induction conditions reflected in Table 3.1. 
Quantification of lipid droplet accumulation was done post differentiation to measure 
efficiency of lipid recruitment. Data is expressed as mean ± SEM. ns = not significant; 




Similarly, in Figure 3.5, across all induction conditions, SC-SVF demonstrated higher 
conversion of pre-adipocytes to mature adipocytes. Visualization of the vast differences 
in the lipid recruitment of OM-SVF and SC-SVF was clearly depicted in Figure 3.6. 
Macromolecular crowding was noted to undoubtedly propel adipogenic conversion rather 





Figure 3.6: Nile Red staining reveals meagre accumulation of lipids by Omental-
SVF compared to Subcutaneous-SVF. OM-SVF and SC-SVF were differentiated under 
the white induction conditions reflected in Table 3.1. Mature adipocytes post 
differentiation were stained for neutral lipids and captured under a fluorescence 
microscope. White induction cocktails: A – Undifferentiated, B – iw, C – iw+MMC, D – 
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iw+AA, E – iw+AA+MMC, F – iw+rosi+BMP4*, G – iw+rosi+BMP4*+MMC, H – ib 
mmc    *BMP4 administered as pre-treatment  
Top and bottom panels show OM-SVF and SC-SVF respectively at x10k magnification 
under different white induction cocktails 
 
Conclusively, after considerable attempts at driving white adipogenesis, the resounding 
choice of SC-SVF to be differentiated into white adipocytes has been substantiated with 
evidence of superior leptin expression, higher adipogenic conversion and lipid 
accumulation as compared to omental-SVF. Reassessment of the standard white 
induction growth factors, indomethacin, IBMX, insulin and dexamethasone, introduced 
Ascorbic Acid as a supplementary adipogenic agent to enhance leptin expression which 
resulted in a high degree of UCP1 suppression for a white phenotype.  
Having established the optimal induction condition for white differentiation of SC-SVF, 
the next step was to look at the stem cell sources to be differentiated into brown 
adipocytes.  As a recap, this model comprises three human stem cell sources that have 
been known to successfully differentiate into functional brown adipocytes; (a) human 
multipotent adipose derived stem cells (hMADS) [72], (b) bone marrow derived MSCs 
(bm MSCs) and (c) SC-SVF [57]. Phenotypic and functional characterization of brown 












3.3 Functional characterization of brown and white adipocytes from various cell 
sources 
A niche ingredient in boosting brown adipose differentiation known as macromolecular 
crowding (MMC) has been reported in the brown differentiation of bone marrow derived 
MSCs (bm MSCs) and SC-SVF [57, 71], but not in hMADs. Therefore, this effect was 
tested in hMADs here and the brown protocol ib and ib mmc have been adapted from Lee 
et.al [57], to be used throughout the duration of the study, where stated (Section 2.2) 
 
Figure 3.7: Brown differentiated hMADs express higher UCP1 mRNA expression 
and enhanced Leptin suppression in the absence of macromolecular crowding 
hMADs were differentiated using brown induction growth factors without (ib) and with 
(ib mmc) macromolecular crowding to determine best differentiation protocol for 
hMADs. Data is expressed as mean ± SEM. ns = not significant; *p < 0.05; **p < 0.01; 
***p < 0.001. N = 3 
 
qPCR analysis in Figure 3.7 showed two-fold suppression of UCP1 in an environment of 
macromolecular crowding and a reciprocal symmetry was observed in leptin expression 
which indicated that the brown phenotype specific to hMADs was boosted without 
macromolecular crowding. Intracellular lipid accumulation as represented by FABP4 
expression reflected similar trends in both conditions. Henceforth, hMADs was 




Full mRNA characterization of all cell sources differentiated to brown adipocytes showed 
comparable UCP1 expression levels in Figure 3.8. Insignificant Leptin expression in SC-
SVF and bm MSCs corroborated well to the brown phenotype with the exception of 
hMADs. FABP4 expression, which indicates adipose maturity, was upregulated in all 
three sources. 
 
Figure 3.8: mRNA expressions show achievement of brown and white differentiated 
adipocytes’ phenotype. A: Human stem cell sources from SC-SVF, bm MSCs and 
hMADs were differentiated into brown adipocytes under their optimal induction 
protocols. B: SC-SVF was differentiated to white adipocytes. Classical brown (UCP1), 
white (leptin) and pan-adipogenic (FABP4) markers were analysed by qPCR. Data is 
expressed as mean ± SEM. ns = not significant; *p < 0.05; **p < 0.01; ***p < 0.001. 
N = 3 
 
Under the respective induction protocols, brown differentiated adipocytes displayed 
definitive conformity to the brown phenotype through the expression of signature UCP1, 
as seen in Figure 3.8, whereas, SC-SVF treated under the white induction protocol of 
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iw+AA exhibits substantial characteristics of white phenotype
 
 
Figure 3.9: Dense lipid accumulation in brown induction across all stem cell sources 
post differentiation. SC-SVF, bm MSCs and hMADS were differentiated to brown 
adipocytes and stained for neutral lipids post differentiation. Fluorescence images were 
taken at x10k (left and middle columns) and x20k (right column) magnifications. 
Quantification of area of lipid accumulation normalized to cell count was also carried out. 




Notable adipocyte conversion was observed in Figure 3.9 for brown differentiated SC-
SVF and bm MSC which corroborated well with FABP4 mRNA expression depicted in 
Figure 3.8. 
 
Figure 3.10: White induction protocol of iw+AA initiates 50% conversion of SC-
SVF pre-adipocytes to white adipocytes. SC-SVF was differentiated to white 
adipocytes and stained for neutral lipids post differentiation. Fluorescence images were 
taken at x10k magnification. Quantification for lipid accumulation normalized to cell 
count was also carried out. Data is expressed as mean ± SEM. ns = not significant; 
*p < 0.05; **p < 0.01; ***p < 0.001. N = 3 
 
 
In addition to significant leptin expression, adipogenic conversion efficiency and mRNA 
expression of FABP4 attested to the state of maturity of adipocytes of both phenotypes; 
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brown (Figure 3.9) and white (Figure 3.10). Following the establishment of mRNA 
expression, UCP1 protein expression in all brown differentiated cell sources was the next 
crucial step for subsequent verification of adipocyte function, as mRNA expression levels 
can be an imprecise indicator of protein expression [121]. 
 
Figure 3.11: Western blot displaying UCP1 protein in both brown and white 
phenotypes. Protein characterization of UCP1 was performed for all stem cell sources 
differentiated to brown adipocytes, according to their respective brown induction 
protocols as well as when stimulated with forskolin. α-tubulin was used as the loading 
control. 
 
Presence of UCP1 protein, displayed in Figure 3.11, was observed in all brown 
differentiated adipocytes, as well as in white differentiated SC-SVF, owing to its beige 
lineage. Upon stimulation by forskolin, UCP1 protein expression increased, with notable 
accumulation in bm MSC and hMADs.  
UCP1 protein-expressing brown differentiated adipocytes confirmed mRNA expressions 
across all cell sources. When adipocytes from all cell sources were exposed to forskolin, 
an adenylyl cyclase activator, to trigger the lipolysis signaling cascade through the 
activation of the β3-adrenoceptor [58], UCP1 protein expression was enhanced, 
suggesting increased transcription of UCP1 protein due to increased cAMP levels. 
Function of brown adipocytes was assessed by the measurement of the oxygen 
consumption rates (Section 2.4) which describes the state its thermogenic activity. Basal 
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respiration, uncoupled respiration and respiratory capacity of the mitochondria were 
measured by the Seahorse Flux Analyzer (Section 2.4) by the addition of metabolic drugs 
including oligomycin, FCCP, Rotenone and Antimycin A in this order, to inhibit 
elements of the electron transport chain. With the addition of forskolin, uncoupled 
respiration was measured to define the functionality of the brown differentiated 
adipocytes. 
 
Figure 3.12: No uncoupled respiration response from white differentiated SC-SVF 
while brown differentiated SC-SVF shows a three-fold increase. Mitochondrial 
function of white and brown differentiated adipocytes from SC-SVF was measured in 
unstimulated (vehicle) and stimulated (forskolin) conditions. All OCR measurements 
(pmol/min) were normalised to DNA count (µg/ml).  
 
Reflected in Figure 3.12 and 3.14, brown differentiated SC-SVF adipocytes showed a 63 
% increase in mitochondrial respiration. Uncoupled respiration showed an enhancement 
of 60% upon stimulation and respiratory capacity was noted to be 72% higher in brown 
adipocytes as compared to white. White differentiated adipocytes showed insignificant 
response to forskolin stimulation despite the expression of UCP1 mRNA and protein in 






Figure 3.13: Forskolin-stimulated hMADs exhibits diminutive extent of uncoupled 
respiration while bm MSCs produce a two-fold increase. Mitochondrial function of 
brown differentiated adipocytes from MSC (ib mmc) and hMADs (ib) was measured in 
unstimulated (vehicle) and stimulated (Forskolin) conditions. All OCR measurements 
(pmol/min) were normalised to DNA count (µg/ml).  
 
Brown differentiated bm MSCs displayed significant uncoupled respiration response to 
forskolin stimulation, observed in Figure 3.13 and 3.14, with a 68 % increase in 
mitochondrial respiration. 
hMADs, on the other hand, exhibited insignificant mitochondrial and uncoupled 
respiration responses. Furthermore, respiratory capacity appeared to be half that of bm 
MSCs. A possible reason could be the high proliferation rate of cells from hMADs which 
may have dampened the effect of uncoupled respiration during normalization of the OCR 




Figure 3.14: Summary of Basal, Uncoupled respiration and Respiratory Capacity of 
SC-SVF White, SC-SVF brown (ib mmc) [top], bm MSC (ib mmc) and hMADs (ib) 
[bottom]. Data are mean ± SEM. ns = not significant; *p<0.05; **p<0.01; ***p<0.001, 
N = 5. 
 
Overall trends in Figure 3.14 indicated that bm MSCs had the highest respiratory capacity 
followed by hMADs and finally brown differentiated SC-SVF.  
Hitherto, what has been established included: 
1) Significant mRNA and protein expression of the exclusive brown phenotypic 
marker of UCP1 in all brown differentiated adipocytes ((a) SC-SVF (ib mmc), 
(b) bm MSC (ib mmc) and (c) hMADs (ib)) 
2) Function of these brown differentiated adipocytes from different cell sources was 
established from measurement of thermogenic activity of UCP1 protein in each 
cell source 
3) Substantial expression of white phenotypic marker, leptin, in white differentiated 
SC-SVF and a high suppression of UCP1 mRNA 
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4) Non-response of white differentiated SC-SVF to a thermogenic stimulant verified 
the inability of the mitochondria to perform uncoupling and thus confirmed its 
white adipose characteristics 
5) Strong indications of lipid accumulation corroborated by the expression of 
FABP4 demonstrated high extent of adipogenic capacity to produce mature 
adipocytes in both brown and white differentiated adipocytes 
6) The role of macromolecular crowding (MMC) to drive adipogenesis to the 
respective phenotype was effective for bm MSCs and SC-SVFs for brown 
differentiation. The MMC effect was negligible in the brown differentiation of 































SC-SVF Donor 1 SC-SVF Donor 1 SC-SVF Donor 1 ib mmc 
SC-SVF Donor 2 SC-SVF Donor 2 SC-SVF Donor 2 ib mmc 
bm MSCs - bm MSCs ib mmc 
hMADs - hMADs ib 
White 




Figure 3.15: Summary of stem cell sources differentiated to brown and white 
adipocytes together with protocol timelines and induction growth factors for high 
throughput microarray screening. A: Final selection of stem cell sources to be 
differentiated to its respective phenotype and the associated induction protocols. B: 
Timeline of induction protocols for both brown and white differentiation. Cells were 
seeded at the same time, where cells designated to differentiate to white adipocytes were 
allowed an extended time to reach confluence when cells designated for brown adipose 
differentiation were pre-treated with BMP7. Both white and brown induction growth 
factors were introduced at the same time. C: List of induction growth factors associated 
withthe phenotype and induction protocol as well as the stem cell source selected for their 
























With the primary adipose cell culture system in place, the next step was to carry out the 
microarray analysis, as described in Section 2.8 accordingly. 
 
3.4 Microarray reveals brown and white adipocyte-associated SLCs 
 
 
Figure 3.16: Heat map revealed phenotypic and time-point clustering which denoted 
distinct molecular profiles between white and brown differentiated adipocytes as 
well as progenitor and mature cells respectively. Microarray analysis was performed 
for genomic analysis of undifferentiated and differentiated adipocytes from various 
human stem cell sources as that listed in the table in Figure 3.15. A heat map was plotted 
where intensity of the color correlated to the expression of fold change.  A: Overall gene 
clustering and B: Clustering of genes in brown differentiated SC-SVF along 0 week, 1 
week and 2 weeks. # and * represent SC-SVF white differentiated adipocytes and 
hMADs brown differentiated adipocytes at 2 weeks post differentiation respectively. 





As observed in Figure 3.16 in panel (A), divergent clustering of brown and white 
differentiated adipocytes highlighted key phenotype differences between both 
populations. Brown differentiated hMADs adipocytes clustered away from brown 
differentiated bm MSCs and SC-SVF at Week 2, suggesting a possible age variation 
factor in the gene clustering, since hMADs was extracted from young donors and SC-
SVF as well as bm MSCs from adults. 
In panel (B), clustering of genes in SC-SVF brown differentiated adipocytes along 
differentiation time-points showed specific set of adipogenic genes activated for the 
process of differentiation. General adherence to the time points as well as phenotype as 
seen in the gene clustering patterns suggested robustness of primary adipose cell culture 
system as well as reliability of the genomic results. 
 
The main objective was to screen for and select SLCs that are present in brown 
differentiated adipocytes. In the first step of the analysis, a pairwise comparison between 
each brown differentiated stem cell source and white adipocytes was performed. Then, 
looking across all brown differentiated cell sources, SLCs that expressed a fold change ≥ 
1.5 and were uniformly differentially expressed were chosen and made into a list of 
brown associated SLCs. In this way, depot specific gene variations were eliminated. 
These SLCs were plotted in Figure 3.17 on graph A. Next, SLCs that expressed a fold 
change ≤ -1.5 and were uniformly downregulated across all brown differentiated cell 
sources were chosen to be cell surface markers for white adipocytes. These SLCs are 






Figure 3.17: Pairwise comparison between BAT and WAT identify brown and white 
specific SLC markers. Gene expression in brown differentiated adipocytes from each 
stem cell source was compared to that in white differentiated adipocytes to identify SLCs 
that were A: brown adipocyte associated and B: white adipocyte associated. Fold change 
cutoff ≥ |1.5|. 
 
As observed in Figure 3.17, 39 SLCs, including UCP1, were identified to be associated 
with brown differentiated adipocytes and 19 SLCs were categorized to be associated with 
white differentiated adipocytes. Next, expression profiles of the 39 brown-associated 
SLCs were studied by looking at their differential expressions between Week 2 (mature 
adipocytes) and Week 0 (progenitor cells) to further choose SLCs that were present on 
mature brown adipocytes. To do this, fold changes of these 39 SLCs from each stem cell 
source were plotted at Week 2 with respect to Week 0, as seen in Figure 3.18. In doing 
54 
 
so, 24 SLCs were eliminated for having no differential expression between mature 





Figure 3.18: Brown associated SLCs - 
Pairwise comparison between Week 2 
and Week 0 across all stem cell sources. 
SLCs identified from pairwise comparison 
between BAT and WAT were cross-
screened against pairwise comparison 
between Week 2 and Week 0 across all 
stem cell sources in both brown 
differentiated adipocytes. SLCs that were 
differentially expressed in two weeks were 
selected. SLCs chosen to be associated 
with brown adipocytes were uniformly 
expressed in all brown differentiated stem 
cell sources.  
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With this plot, SLCs that showed consistent upregulation across all brown differentiated 
stem cell sources with fold change ≥ 1.5 were chosen. Therefore, inconsistent expression 
patterns of SLCs between cell sources were disregarded. For example, from Figure 3.18, 
SLC2A5 was upregulated in brown differentiated hMADs but downregulated in bm MSC 
and SC-SVF. Therefore, SLC2A5 as well as SLC25A15 were excluded. 
As UCP1 was expressed at a basal level in white adipocytes with a fold change of 1.5 
expressed in the microarray, I considered the fold-change of 1.5 as a point of significance 
when taking into account SLCs that were expressed in both brown and white adipocytes. 
Where the ratio of fold change of SLC present in brown adipocytes to fold change of 
SLC present in white adipocytes was   ≥ 1.5, these SLCs were included to the final list. In 
doing so, SLC29A1 and SLC6A20 were eliminated. The final list of brown adipogenic 
SLCs is reflected in Table 3.3. 
 
The next step was to look at the expression profiles of the 19 white-associated SLCs by 
studying their differential expressions in all cell sources between Week 2 (mature 
adipocytes) and Week 0 (progenitor cells) to further choose SLCs that were present on 
mature white adipocytes. Figure 3.19 clearly showed the upregulation of 11 out of 19 
SLCs to be present on white differentiated adipocytes. To further tighten this criterion, 
SLCs that were downregulated in brown differentiated adipocytes across stem cell 
sources were chosen. Thus, a list of three white adipogenic SLCs was compiled in Table 
3.4. 
 




Figure 3.19 White associated SLCs - 
Pairwise comparison between Week 
2 and Week 0 across all stem cell 
sources. SLCs upregulated in white 
adipocytes were cross-compared to 
SLCs upregulated at two weeks.  SLCs 
chosen to be associated with white 
adipocytes were uniformly 
downregulated in all brown 





Figure 3.20: Workflow of categorization of brown and white associated SLCs. 1. A 
pairwise comparison of brown and white adipocytes was carried out. For brown 
associated SLCs: SLCs that were overexpressed in brown differentiated adipocytes in all 
four stem cell sources were chosen. 2. These SLCs identified from step 1 had to be 
upregulated in mature brown adipocytes across all four brown differentiated cell sources. 
Fold change cutoff ≥ 1.5. 3. Where SLCs present in brown differentiated adipocytes 
across all four stem cells exhibited an expression in white differentiated adipocytes, the 
ratio of fold change of this brown associated SLCs is to its fold change in white 
differentiated adipocytes was ≥ 1.5. 4. Finally, these SLCs were deemed as brown 
associated. For white associated SLCs: 1. A pairwise comparison of brown and white 
adipocytes was carried out. SLCs that were downregulated in brown differentiated 
adipocytes in all four stem cell sources were chosen. 2. These SLCs identified from step 
1 had to be upregulated in mature white adipocytes. Fold change cutoff ≥ 1.5. 3. These 
SLCs from step 2 had to be uniformly downregulated in all four brown differentiated cell 
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FC ≥ 1.5
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Adipose maturity filtering 
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Tables 3.3 and 3.4 present brown and white associated SLCs respectively for further 
validation and study. 
 
Gene 
Av. Fold Change 
across 4 brown 
sources 
Cellular Component Substrates 
SLC7A10 77.2 Plasma membrane Amino Acids 
SLC29A4 14.9 Plasma membrane Monoamines 
SLC1A3 10.8 Plasma membrane Glutamate/Aspartate 
SLC5A3 8.2 Plasma membrane Inositol/Glucose 
SLC22A5 8.1 Plasma membrane Carnitine/Organic cations 
UCP1 6.2 Inner mitochondrial 
membrane 
H+ 
SLC19A3 4.8 Plasma membrane Thiamine 
SLC9A3 4.1 Plasma membrane Na+/H+ 
UCP2 3.3 Inner mitochondrial 
membrane 
H+ 
SLC25A13 3.2 Mitochondria Glutamate/Aspartate 
SLC25A11 3.2 Mitochondria Malate 
Table 3.3: Overexpressed solute carrier (SLC) genes in brown differentiated 









SLC24A6 8.5 Plasma membrane Na+, Li+, Ca2+ 
SLC39A14 5.0 Plasma membrane Zn, Fe, Mn, Cd 
SLC15A3 4.0 Plasma Membrane H+, Peptides, Histidine 
Table 3.4: Novel solute carrier (SLC) genes differentially expressed in white 







3.5 Validation of identified brown and white adipocyte-associated SLC
 
Figure 3.21: qPCR validation of SLCs derived from microarray authenticates five 
out of ten brown associated SLCs. Verification of SLCs identified in microarray by 
qPCR. SLC7A10 = Neutral amino acid transporter; SLC19A3 = Thiamine transporter; 
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UCP2 = Uncoupling protein 2; SLC29A4 = Plasma membrane monoamine transporter; 
SLC5A3 = Sodium/Myo-Inositol Cotransporter; SLC22A5 = Sodium dependent Carnitine 
transporter; SLC1A3 = Glutamate/Aspartate transporter; SLC25A13 = Citrin; SLC25A11 
= Oxoglutarate/malate transporter; SLC9A3 = Sodium/Hydrogen Exchanger; Data is 




Figure 3.22: Verification of SLCs identified in microarray by qPCR show SLC8B1 
and SLC15A3 inclining toward white adipogenic markers. Verification of SLCs 
identified in microarray by qPCR SLC39A14 = Zinc transporter 14; SLC8B1 = 
Mitochondrial Na+/Ca2+ exchangers; SLC15A3 = Proton-coupled oligopeptide 












Table 3.5: Final list of brown and white associated SLCs validated by qPCR 
 
SLC39A14 displayed preferential expression in pre-adipocytes rather than in white 
adipocytes, seen in Figure 3.22. Despite insignificant expressions of SLC8B1 and 
SLC15A3 in white differentiated SC-SVF, evident downregulation of these markers 
across brown differentiated cell sources present as worthwhile leads for future studies 




From a total of 10 new SLCs that were identified, five SLCs; SLC7A10, SLC19A3, 
SLC29A4, SLC22A5 and SLC1A3 (Table 3.5) mirror qPCR expression as that 
exemplified by microarray, as observed in Figure 3.21 and comparing to the list in Table 
3.3. Out of a total of 5 validated brown associated SLCs, this study went on to examine 
two SLCs in greater detail, (a) SLC19A3 and (b) SLC22A5, to explore their link to 
BAT’s function. Both SLCs were chosen for their known direct and crucial roles in 
energy metabolism, namely glucose metabolism for SLC19A3 and lipid metabolism for 
SLC22A5. 
 
3.6 SLC19A3 and SLC22A5 are important in maintaining brown phenotype in 
brown differentiated adipocytes 
SLCs, being solute carriers, are largely defined by the substrates that they transport. In 
the case of SLC19A3, the predominant substrate that it transports is thiamine. Also 
known as Vitamin B1, thiamine is not synthesized by the human body [122] and plays a 
key role in glucose metabolism [123], although it has not been remotely linked to BAT 
function. mRNA expression of SLC19A3 showed expression levels in both white and 
brown differentiated cell sources with superior expression in brown differentiated cell 
sources (Figure 3.19). Protein detection could only be identified in brown differentiated 





Figure 3.23: Protein expression of SLC19A3 is strongly detected in only bm MSCs 
(ib mmc). Western blot for protein detection of SLC19A3 was performed for all stem 
cell sources differentiated to brown adipocytes, according to their respective brown 
induction protocols. α-tubulin was used as the loading control. 
 
Also, from microarray results (Figure. 3.17) and qPCR validation (Figure. 3.21), 
SLC19A3 which was highly expressed in brown adipocytes highlighted an important 
correlation between the transporter, thiamine and BAT phenotype. Thus, it was 
hypothesized that supplementing thiamine as an induction growth factor during 
differentiation enhances the mRNA expression of UCP1. Owing to positive protein 
expression in brown differentiated bm MSCs, bm MSCs was used to perform subsequent 




Figure 3.24: Supplementation of Thiamine as an induction growth factor in brown 
differentiated MSCs yields no differences in expression levels of UCP1, Leptin and 
FABP4. Thiamine was added as an additional growth factor in the brown induction 
protocol (ib mmc) in bm MSCs, in varying concentrations ranging from 0.01 µM to 1000 
µM. After which, qPCR analysis of UCP1, SLC19A3, Leptin and FABP4 was performed. 
Data is expressed as mean ± SEM. ns=not significant; *p < 0.05; **p < 0.01; 
***p < 0.001. N = 3 
 
From Figure 3.24, addition of thiamine was found to have no effect on UCP1, leptin and 
FABP4 expressions. An examination of the growth factors present in the standard 
DMEM media revealed presence of thiamine hydrochloride [124], which may have 
caused a saturation thiamine to be present thus, a saturation of UCP1 mRNA expression. 
Therefore, inhibition of SLC19A3 to demonstrate brown adipocytes’ need for thiamine 
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transported specifically by this transporter would make a strong case, however, no known 
appropriate inhibitor for SLC19A3 was available for this study. Overexpression of 
SLC19A3 in brown over white differentiated adipocytes highlights brown adipocytes’ 
significant need for thiamine to maintain its phenotype, and may suggest a role for 
thiamine as a browning agent. 
 
Next SLC of interest is SLC22A5, a high affinity Na+ carnitine transporter [86, 98].  
SLC22A5 protein is detected in the highest amount in bm MSCs and in trace amounts in 
SC-SVF and hMADs as seen in Figure 3.25. 
 
Figure 3.25: Expression of SLC22A5 protein in all three stem cell sources of brown 
adipocytes, with highest detection in bm MSCs (ib mmc). Immunohistochemistry 
detection of SLC22A5 was performed for all stem cell sources differentiated to brown 
adipocytes, according to their respective brown adipocyte induction protocols. α-tubulin 
was used as the loading control. 
 
Also denoted as OCTN2, SLC22A5 allows the uptake of carnitine into the cell. Carnitine 
is an important messenger compound that transports long chain free fatty acids, otherwise 
impenetrable to the mitochondria, from the cytosol to the mitochondria matrix for it to 
enter the β-oxidation for fatty acid metabolism [125, 126]. In doing so, fatty acids 
accumulated in the cell are efficiently utilized. The roles of SLC22A5 and carnitine, thus 
have a direct association with the function of BAT since it is free fatty acids that activates 
UCP1 (Section 1.2.2.2).  According to Figure 3.21, SLC22A5 was expressed 
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significantly in brown differentiated bm MSCs, as well as SVF and hMADs and not 
expressed in white differentiated SVF. 
A study probing into the role of carnitine as a lipolytic agent found that 0.1 µM of 
carnitine was enough to induce lipolysis with glycerol release of 1.5-fold in murine 
adipocytes [127]. Since presence of carnitine in the cell enhances the uptake of fatty acids 
into the mitochondria and thus influences lipid metabolism, it was hypothesized that 
carnitine increases the amount of fuel needed to support a thermogenic response in brown 
adipocytes. Therefore, the same amount of carnitine (0.1 µM) would exhibit a lipolytic 
effect on brown differentiated adipocytes. In the ensuing experiments, carnitine was 
investigated as a thermogenic stimulant in brown differentiated bm MSCs, as bm MSCs 
display the highest mRNA and protein expression of SLC22A5, as observed in Figures 






Figure 3.26: Carnitine stimulation does not enhance uncoupled respiration in brown 
differentiated MSCs (ib mmc). Brown differentiated MSCs were stimulated under 4 
conditions (a) vehicle (b) forskolin (c) 0.1 µM carnitine and (d) 0.1 µM carnitine + 
forskolin to test the effect of carnitine as a lipolytic stimulant and hence investigate its 
enhancement of BAT function. All OCR measurements (pmol/min) were normalised to 
DNA count (µg/ml). Data is expressed as mean ± SEM. ns=not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001. N = 5 
 
From Figure 3.26, addition of 0.1 µM carnitine [127] and vehicle both showed the same 
outcomes in indicating no uncoupled respiration. Furthermore, addition of 0.1 µM to a 
known potent activator of lipolysis, forskolin, yields no significance in enhancement of 
uncoupled respiration, which could suggest that the concentration of 0.1µM carnitine 
could be too low for lipolysis in human cells, since this concentration was used in murine 
adipocytes. Before ruling out carnitine as having negligible effect on lipolysis, the next 
step was to study the effect of administering carnitine in varying concentrations on brown 
differentiated bm MSCs to optimize the concentration of carnitine needed to stimulate 





Figure 3.27: Carnitine is not a lipolytic agent. Bm MSCs were differentiated under the 
brown induction protocol (ib mmc). At the end of the differentiation cycle, Forskolin and 
varying concentrations (0.1 µM, 1 µM, 10 µM, 100 µM) of carnitine were added to the 
brown adipocytes for 16 hours in fatty acid free media to investigate the extent of 
lipolysis. 16 hours later, cells were imaged, and quantified by area of lipid accumulation 
normalized to cell count. Data is expressed as mean ± SEM. ns=not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001. N = 3 
 
A range of concentrations from 0.1 µM to 100 µM was added to brown differentiated bm 
MSCs post differentiation to test the effect of carnitine as a lipolytic agent. Conclusively, 
as in Figure 3.27, carnitine showed no effect on lipolysis with quantification of lipid 
accumulation remaining constant irrespective of quantity of carnitine added.  
In another study done on juvenile visceral steatosis (JVS) mice where there is a mutation 
on the SLC22A5 gene, BAT in these mice shared similar characteristics as WAT, 
reduced UCP1 mRNA, cold intolerance and impaired thermogenesis [128]. This suggests 
the importance of carnitine in maintaining a brown phenotype in BAT. The following 
hypothesis was that carnitine was a promotor of brown adipogenesis and increases the 
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expression of UCP1. Thus, adding carnitine as an induction growth factor during brown 
adipocyte induction would enhance the UCP1 expression. 
 
Figure 3.28: Carnitine induction of brown differentiated bm MSC (ib mmc) 
accentuates UCP1 expression. Carnitine was added in varying concentrations (0.01µM, 
0.1 µM, 10 µM and 1000 µM) as an additional induction growth factor to the brown 
induction protocol in MSCs. qPCR was performed to study the expressions of UCP1, 
SLC22A5, leptin and FABP4. Data is expressed as mean ± SEM. ns=not significant; 
*p < 0.05; **p < 0.01; ***p < 0.001. N = 3 
 
A 2.5-fold increase in UCP1 expression was observed when 0.1 µM of carnitine was 
added as shown in Figure 3.28. FABP4 expression levels remained constant regardless of 
concentration of carnitine which suggested no impairment caused by carnitine on the 
differentiation capacity of the bm MSCs. SLC22A5 remained constant which indicated 
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that at 0.1 µM concentration of carnitine, the kinetics of carnitine transport was highly 
enhanced for brown differentiation. A reciprocal symmetry was also observed in leptin 
expression which corroborated the effect of carnitine on the brown phenotype. Next, the 





Figure 3.29: Enhanced UCP1 mRNA does not translate into a higher degree of 
uncoupled respiration. Bm MSCs were differentiated to brown adipocytes under 2 
distinct conditions (a) ib mmc without carnitine and (b) ib mmc with 0.1 µM carnitine as 
an induction growth factor. At the end of the differentiation, both conditions were 
stimulated under vehicle and Forskolin to study the OCR response. All OCR 
measurements (pmol/min) were normalised to DNA count (µg/ml). Data is expressed as 




Despite the enhanced UCP1 mRNA, degree of uncoupled respiration remained 
unchanged when compared to brown differentiated bm MSCs that received no carnitine 
























Chapter 4: Discussion 
4.1 Validation of human brown adipose system 
In the buildup to validate hypothesis 1 that was to identify SLC markers to distinguish 
BAT and WAT, stem cells from various anatomical locations in humans were 
differentiated into functional brown adipocytes with known validation [57, 71, 72, 129].  
Lack of access to human brown adipose tissue underlines the need for human brown 
adipocyte cell culture system. Concurrence of gene regulation in differentiated brown 
adipocytes with proteomic analysis of human BAT biopsies is key to corroborating in-
vitro cell culture studies and takes us a step closer to building important in vivo-
resembling BAT models for human therapeutic strategies of combating metabolic 
disorders. In this study, notable genes namely KCNK3, ARG2, CKMT1A, CKMT1B, 
CD36 have been observed to be highly upregulated in brown differentiated adipocytes 
across all cell sources and have been reported to be highly enriched in human BAT 
biopsies [38, 59, 130]. Furthermore, a total of 89 genes upregulated in brown 
differentiated adipocytes across all cell sources in this array was found to be present in a 
proteomic analysis of human deep neck BAT biopsies. Amongst the 89 genes, three 
mitochondrial SLCs (SLC25A4, SLC25A10 and SLC25A11) have also been identified as 
well as the CPT2 gene which plays an important role in the carnitine biochemistry 
pathway that includes SLC22A5 as identified and verified in this study [130]. Altogether, 
this highlights the niche potential of the differentiation protocol to produce brown 
adipocytes that possess gene signatures identified in human BAT biopsies. In this adipose 
system, the robustness of the SLC expression was challenged with the availability of four 
cell sources of brown differentiated adipocytes. Furthermore, establishing the white 
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differentiated adipocyte control led to the novel discovery of ascorbic acid as a potent 
suppressor for UCP1 expression, as well as a promoter for leptin expression. 
Conclusively, this primary brown adipose system is validated for high functionality in 
tune with the respective phenotypes and provides the confidence that the genomic data 
derived from it was reliable. 
 
4.2 Microarray reveals novel SLCs important to BAT and WAT 
Much effort has been spent to understand human BAT at a molecular level, for its 
beneficial functional capabilities to be acutely exploited [59, 131, 132]. The goal of this 
study was to identify novel brown and white SLCs for future therapeutic targeting, as 
stated in hypothesis 1. In this study, an SLC marker panel consisting of brown and white 
associated SLCs had been generated following an extensive screening process in ensuring 
that the brown and white associated SLCs were unanimously present and absent, 
respectively, in brown mature adipocytes from four human cell sources known to produce 
functional brown adipocytes. The SLC marker panel, presented in Table 4.1, consists of a 
brown associated SLC (SLC7A10) that has been reported in human adipose biology, two 









Significance of SLC marker panel in 
existing human adipose biology literature 









Table 4.1: List of SLCs identified in present study categorized according to 
relevance to human adipose biology in current literature 
 
Lack of knowledge of these SLCs with no identifiable links to adipose biology leaves 
abundant room for conjecture about its exact mechanisms and how it links to BAT 
function and stimulation, if at all. 
Also known as amino acid transporter 1 (Asc-1) SLC7A10 is a sodium independent 
neutral amino acid transporter responsible for the transport of amino acid substrates such 
as alanine, serine, cysteine and glycine in the brain [133]. Asc-1 is reported to be a white 
adipose marker in mice and humans [63]. Typical WAT depots in mice of perigonadal 
and perirenal displayed high expressions of Asc-1 and low expression in interscapular fat, 
a BAT depot. In humans, Asc-1 expression was insignificant and exhibited patterns 
similar to that in subcutaneous and deeper fat depots from the neck (carotid sheath and 
longus colli), where carotid sheath and longus colli are BAT enriched depots[63], 
suggesting that Asc-1 could possibly be a beige marker instead of white, since 
subcutaneous fat may contain both white and beige cells. In this present system, Asc-1 
was expressed in brown differentiated adipocytes in all stem cell sources and low 
expression in white differentiated SC-SVF adipocytes. One limitation from this system in 
this study was inaccessibility of the neck fat depot where most BAT is found in adults, 
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which would probably be useful in revealing Asc-1 expression. Asc-1 positive expression 
in WAT in mice and in brown adipocytes in this system could suggest inter-species 
differences in expression. In another study, Asc-1 expression in UCP1-positive 
subcutaneous tissue samples in lean and obese children and adult showed similar 
observations to UCP1-negative adipose samples [134]. Although this could further 
support the claim that Asc-1 could be a beige marker, ultimately, verification of this has 
to be carried out by studying Asc-1 expression in different human BAT depots, other than 
in the neck, to prove that Asc-1 is indeed present in beige/brown adipose. 
SLC8B1, previously known to be SLC24A6, is an inner mitochondrial membrane-
localized Na+/Ca2+ exchanger. Central to mitochondria function is intracellular Ca2+ 
signaling where it modulates energy metabolism by controlling important aspects of ATP 
production. According to the qPCR validation in this study, SLC8B1 was downregulated 
in brown differentiated adipocytes and expressed in white differentiated adipocytes. It has 
not been directly described in WAT literature, however, remote studies have linked the 
effects of fenofibrate, a cholesterol-reducing drug for the treatment of  
hypertriglyceridemia, to increased secretion of adiponectin, a protein abundantly secreted 
by WAT [135]. Interestingly, a genome-wide study on the effects of fenofibrate on 
plasma adiponectin picked out SLC24A6/SLC8B1 as a gene locus for adiponectin 
signaling related to metabolic syndromes such as type 2 diabetes [136]. The implications 
of these remain to be thoroughly investigated. Apparent downregulation of SLC8B1 in 
brown differentiated adipocytes across all stem cell sources as well as expression in white 
differentiated OM-SVF and SC-SVF (Supplementary Data A) may present a case for it to 
be a novel WAT marker. 
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SLC15A3 belongs to the family of electrogenic transporters that exploit the proton-
motive force for uphill transport of short chain peptides and peptide-mimicking structures 
into the cells [137]. PhT2, as it is alternatively known, is an integral membrane protein 
expressed in rat and human intestinal cells that transport free histidine and certain di- and 
tripeptides. Compared to the rest of its family members, little is known about SLC15A3 
and its exact function [138]. Absence of SLC15A3 in brown differentiated adipocytes in 
all stem cell sources (Supplementary Data A) could indicate a possible role in WAT. 
SLC29A4 was identified, in this current study, to be an SLC that was exclusively found 
on brown differentiated adipocytes. It belongs to the family of equilibrative nucleoside 
transporter and is alternatively known as plasma membrane monoamine transporter 
(PMAT) due to its low interaction with nucleosides. It is expressed in several tissues, 
with highest expression in brain where it transports monoamine neurotransmitters such 
as, serotonin, dopamine, and norepinephrine [139]. It has also been reported to interact 
with organic cations and postulated to function as a poly-specific organic cation 
transporter [140, 141]. No known literature has been reported linking PMAT to adipose 
tissue in any way.  Conceivably, its transport of the neurotransmitters norepinephrine and 
dopamine could offer clues as to how it plays a role in brown adipocytes and presents as 
a novel brown adipose marker. 
Encoding the glutamate transporter GLAST and also known as EAAT1, SLC1A3 is 
highly expressed in the cerebellum where it is a glial high affinity glutamate transporter 
[142]. With no reported associations to adipose biology, SLC1A3 is a novel discovery as 
a brown associated SLC from its expression in all brown differentiated adipocytes and 
absence in white differentiated adipocytes. 
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ThTr-2 or SLC19A3 is described as a thiamine transporter with highest expression in 
duodenum and localized to the apical membrane in intestinal cells[143], clarifying its’ 
expression in the intestine for thiamine absorption since thiamine is not produced by the 
body and has to be obtained from external sources[123].  In this study, SLC19A3 was 
expressed in brown differentiated adipocytes across all stem cell sources and 
insignificantly expressed in white differentiated adipocytes. Thiamine is implicated in 
both type 1 and type 2 diabetes, attributing thiamine deficiency as a hallmark 
manifestation of hyperglycemia [144]. Thiamine is also known to interact with enzymes 
involved in glucose metabolism as well as Krebs’ cycle [123, 144], thus an important 
mediator in energy metabolism.  
SLC22A5 or OCTN2 is known as the sodium-dependent, high affinity carnitine 
transporter. It plays a crucial role of transporting carnitine which is essential for the 
transport of activated long chain free fatty acids in the cell into the mitochondrial matrix 
for β-oxidation [145]. Carnitine is also involved in the transfer of by-products from 
peroxisomal β-oxidation, where the peroxisome is the site of breakdown for very long 
chain fatty acids [127]. With intimate links to lipid metabolism through the β-oxidation 
cycle coupled with the fact that SLC22A5 transporter has been identified in this current 
study exclusively in brown differentiated adipocytes and not in white differentiated 
adipocytes, studying the effects of carnitine on BAT function could be meaningful. 
Much has been speculated about the possible roles these identified SLCs can play in BAT 
and WAT function. Despite the fact that there are significant gaps in knowledge about 
these SLCs, the presence of these SLC markers, distinguishing BAT and WAT validates 
hypothesis 1.  
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Of the possible five brown associated SLCs for further investigation, three SLCs share 
common expression profiles in the brain and are described to modulate brain-related 
activities whereas the remaining two leave room for direct and assessable 
pharmacological regulation by its known substrates of thiamine (SLC19A3) and carnitine 
(SLC22A5). Furthermore, both thiamine and carnitine play crucial roles in glucose and 
lipid metabolism respectively, which warranted subsequent investigation in uncovering 
their roles in relation to BAT. As the main goal was to probe and enhance the function of 
BAT as part of hypothesis 2, investigative studies into the roles of identified white 
associated SLCs was not pursued here. 
 
4.3 Importance of thiamine and carnitine in BAT phenotype 
In addressing hypothesis 2, the substrates predominantly transported by SLC19A3 and 
SLCC22A5 were used to investigate their effect on BAT differentiation and function. 
As briefly described in the previous section, SLC19A3 is a thiamine transporter with 
major expression in intestinal cells [143]. Thiamine is an important nutrient and stored in 
the brain, skeletal muscle, heart and kidneys. It has a major role in glucose metabolism. 
As soon as thiamine is transported into the cell, it is converted into thiamine diphosphate 
which is a crucial co-enzyme for transketolase enzyme and the dehydrogenase complexes 
for pyruvate, α-ketoglutarate and branched-chain keto acids needed for oxidative 
metabolism [122, 123, 144, 146]. Deficiency in thiamine impairs ATP production and 
disturbs energy homeostasis [146] as well as insulin synthesis [122]. Also, as thiamine 
deficiency has been described in individuals with type 1 and 2 diabetes, thiamine 
supplementation has been reported to reverse the damaged caused by hyperglycaemia 
[122, 144]. In this case, qPCR validation of SLC19A3 showed significant upregulation in 
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brown differentiated SVFs (460 fold), bm MSCs (4000 fold) and hMADs (580 fold) 
which suggested a metabolic significance of thiamine in BAT function. Addition of 
thiamine to brown differentiated bm MSCs showed no effect on UCP1 mRNA 
expression, which could be attributed to the presence of 12 µM of thiamine hydrochloride 
in the DMEM media, which may have possibly caused a saturation of thiamine leading to 
the saturation of UCP1 expression in the brown differentiated adipocytes. Furthermore, 
loading an additional 10 µM of thiamine decreased UCP1 expression by two-fold (60 to 
30) and correspondingly, SLC19A3 expression fell by 20% (fold change 420 to fold 
change 340), suggesting a correlation between thiamine, and UCP1 and SLC19A3 
expressions.  Inhibiting SLC19A3 will confirm the role of thiamine in the maintenance of 
BAT phenotype however, lack of a suitable inhibitor for SLC19A3, at this point, leaves a 
gap in knowledge in determining the correlation between thiamine and UCP1. Also, 
overexpression of SLC19A3 in brown over white differentiated adipocytes could possibly 
suggest a role for thiamine as a browning agent since both brown and white 
differentiation were carried out using the same DMEM media with exposure to the same 
concentration of thiamine hydrochloride. 
 
As a high affinity carnitine transporter, SLC22A5 plays an important role in shuttling free 
fatty acids into the mitochondria for fuel burning in the β-oxidation cycle [86, 125, 127, 
147]. In mature murine adipocytes, supplementation of 0.1 µM carnitine induced the 
release of intracellular lipid accumulation as well as downregulation of brown adipogenic 
markers PPARγ and FABP4 [127]. In contrast, carnitine did not induce any lipolysis in 
brown differentiated bm MSCs. This was substantiated by no change in uncoupled 
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respiration when 0.1 µM carnitine was administered as a thermogenic stimulant, even 
when 0.1 µM of carnitine was added together with forskolin. Subsequently, evidence of 
JVS mice that suffer from a defect in the SLC22A5 gene reported BAT mitochondria as 
that of resembling WAT, impaired thermogenesis, low UCP1 mRNA, cold intolerance 
and enlarged lipid vacuoles [128]. This suggested that carnitine was an important 
compound for BAT to maintain its phenotype and formed the basis of the next 
hypothesis; adding carnitine as an induction growth factor boosts UCP1 expression. 
Upregulation of UCP1 mRNA was observed when carnitine was induced during brown 
differentiation with a 2.5-fold increase (50 to 132) when 0.1µM carnitine was used. Yet, 
functional characterization of carnitine-boosted brown differentiation showed negligible 
increase in uncoupled respiration. As a whole, this data suggests that carnitine is 
important for brown adipocyte differentiation in humans by possibly increasing the 
transcription of PPARγ, since it has been reported that regulation of PPARγ expression 
was linked to carnitine supplementation in 3T3-L1 adipocytes [127], and therefore, 
UCP1, but may not play a role in activating UCP1, despite being able to enhance fatty 







Figure 4.1: Proposed role of carnitine: Augments brown differentiation but does not 
enhance thermogenesis in humans. (A) During brown differentiation, carnitine may 
play a role to increase the master regulator for adipogenesis, PPARγ, and in turn, UCP1. 
(B) Enhanced transport of long chain fatty acids into the mitochondria via carnitine does 
not contribute to enhanced thermogenesis since fatty acids directly enter the 
mitochondrial matrix. Fatty acid oxidation may increase overall but degree of uncoupling 
remains unchanged. 
 
Deeper studies are needed to probe into carnitine’s role in human BAT phenotype 
maintenance and function. Presence of carnitine in human serum [148] could be inferred 
to be present in fetal bovine serum used as a co-addition in all media formulations. Thus, 
varying carnitine concentration, by variation of FBS content, could simulate carnitine-
starved conditions to the cells to study importance of carnitine to brown phenotype from 
correlation to UCP1 mRNA expression. First step in this experiment would be to quantify 
the amount of carnitine present in FBS. Additionally, the effects of poor BAT phenotype 
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exhibited by JVS mice with the SLC22A5 gene defect were reversed with the 
supplementation of carnitine [128]. This brings to light another channel for carnitine 
transport, which has been suggested to be via the low affinity carnitine transporter 
SLC22A4, but more importantly, the urgent need of carnitine by BAT to maintain its 
brown phenotype. The use of SLC22A5 inhibitor cefepime hydrochloride, a class of β-
lactam antibiotics [149], simultaneously with the inhibition of SLC22A4 to ensure total 
deprivation of carnitine to the adipocyte will be key to demonstrating the role of carnitine 
in BAT.  
 
Chapter 5: Conclusion and Future Outlook 
Here, I report for the first time, a systematic SLC study done in brown differentiated 
adipocytes from four human stem cell sources that displayed gene expression patterns 
similar to proteomic expressions in human BAT biopsies. What has been achieved was 
the derivation of an SLC marker panel that delineated brown and white adipocytes, thus 
providing worthwhile leads on BAT function enhancement. Though substrate modulation 
through two of the SLCs have shown effects on BAT differentiation but stopped short on 
boosting BAT function, headway has been made in confirming the importance of the role 
of SLCs in BAT and understanding the intricacies of BAT cell signaling and function. 
The SLC marker panel is an invaluable starting point for delving into non-adrenergic 
targeting of BAT by means of biochemical intervention that is possible to translate to 
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Appendix – Supplementary Data A 
 
Figure S1: White adipogenic markers of SLCB1 and SLC15A3 identified by array 
show potential from expression in white differentiated OM-SVF and SC-SVF cell 
sources.  
